Navigation Links
Medifast Announces Third-Quarter 2007 Results
Date:11/8/2007

We are excited that we are experiencing positive trends in our overall business including increases in revenues over 2006 in all aspects of our business. The true effect of these investments will be in the near future as the company continues its long term growth plan," said Michael S. McDevitt, Chief Executive Officer.

"We are pleased with Take Shape for Life, the Company's direct selling channel which is experiencing both significant growth in revenue and the recruiting of new health coaches. The momentum in Take Shape for Life has been fueled by our strategic investments in field training as well as a highly successful National Convention. The Medifast Weight Control Centers model is in high demand in targeted markets and is at a very exciting stage in its development. The Company plans to expand this highly successful model in 2008 and we are confident that the investments made in this business in the second and third quarters of 2007 will allow this business to be a driver of revenues and profits in the upcoming year," continued McDevitt.

"The Company is also very pleased with the positive trends we are seeing with our new celebrity endorsed advertising campaign that includes television, print, and online media. Testing of this advertising campaign featuring Emmy(R) award winning actress Genie Francis and movie star Kristy Swanson began late in the third quarter as well as a continued public relations effort which included Genie and Kristy representing the Medifast brand on national television shows and in print publications. The advertising testing which started late in the third quarter highlighted the celebrities at the beginning stages of their program. Because of its proven effectiveness, the company has invested in a new campaign for the first quarter of 2008, which will showcase two times the weight loss by both women on the Medifast program since the third quarter campaign. The company anticipates continued major media coverage throughout th
'/>"/>

SOURCE Medifast, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Medifast Announces Winners of Mother-Daughter Challenge
2. Medifast, Inc. Announces Support for Microsoft HealthVault
3. Medifast Announces Updated Full Year 2007 Guidance
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 2Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 3Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 4BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4ACTEMRA 28R 29 28tocilizumab 29 Studies to be Featured at the European League Against Rheumatism 28EULAR 29 Congress 47894 1ACTEMRA 28R 29 28tocilizumab 29 Studies to be Featured at the European League Against Rheumatism 28EULAR 29 Congress 47894 2ACTEMRA 28R 29 28tocilizumab 29 Studies to be Featured at the European League Against Rheumatism 28EULAR 29 Congress 47894 3ACTEMRA 28R 29 28tocilizumab 29 Studies to be Featured at the European League Against Rheumatism 28EULAR 29 Congress 47894 4SignatureForum Reveals Top Rated Aesthetic Medical Practices in U S 47889 1SignatureForum Reveals Top Rated Aesthetic Medical Practices in U S 47889 2SignatureForum Reveals Top Rated Aesthetic Medical Practices in U S 47889 3Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 1Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 2Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 3Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 4Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 5